Detailed product reference
Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.
Product overview
Skyrizi is an IL-23-p19 antibody. This record covers Japanese 55/75/150 mg SC products, separate from IBD presentations.
Read source section ↗Mechanism of action
Neutralizes IL-23 by binding its p19 subunit and reduces downstream inflammatory signaling.
Read source section ↗Japanese indications & eligibility
Selected psoriasis/PsA variants and formulation-dependent palmoplantar pustulosis; pediatric 55 mg provisions differ.
Read source section ↗Administration & dose differences
Usually doses at week 0, week 4 and every 12 weeks thereafter; pediatric dose is weight-based from age six.
Read source section ↗Adverse effects & key risks
Watch serious infection, TB, hypersensitivity and injection reactions throughout the dosing interval.
Read source section ↗Contraindications & special populations
Contraindicated in serious infection, active TB and ingredient hypersensitivity.
Read source section ↗Drug interactions
Review live vaccines and other immunomodulators; self-injection requires training.
Read source section ↗Assessment & monitoring
Assess TB/infection and monitor skin/joint response, handling and adverse symptoms.
Read source section ↗Storage & handling
Refrigerate at 2–8°C, protect from light, do not freeze or shake; follow device-specific instructions.
Read source section ↗Sources & verification
Product checked ·
- PMDA electronic package insert ↗www.pmda.go.jp
Primary source for mechanism, indications, doses and risks; revision: 2026-09.
- Manufacturer information ↗skyrizi.jp
Official product or related information; professional portals may require identity confirmation.
- Wikipedia: ingredient background ↗en.wikipedia.org
Background reference; Japanese approvals and administration are governed by PMDA sources.
